{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:13:49Z","timestamp":1789427629722,"version":"build-2803163510"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Most non-polio <jats:italic>enterovirus<\/jats:italic> infections in immunocompetent individuals are acute and self-limiting in nature; however, infection can be severe, chronic and have devastating outcomes in immunocompromised hosts. Therapeutic strategies have predominantly involved supportive care, with the lack of approved antiviral treatments proving challenging for management. We report a case of an 8-month-old child who presented with severe <jats:italic>enterovirus<\/jats:italic> encephalitis following gene therapy for X-linked severe combined immunodeficiency (X-SCID) and who demonstrated clinical and microbiological improvement after a novel regimen of favipiravir, fluoxetine, and high-dose intravenous immunoglobulin (IVIg). The patient presented 6 weeks post\u2013gene therapy with rapid neurological deterioration in the context of incomplete immune reconstitution, with microbiological and radiological evidence confirming <jats:italic>enterovirus<\/jats:italic> encephalitis. His neurologic examination stabilised 8 weeks after treatment, and he subsequently demonstrated excellent immune recovery. This is the first case report of combined therapy with favipiravir, fluoxetine, and high-dose IVIg in the context of severe <jats:italic>enterovirus<\/jats:italic> encephalitis in an immunocompromised host. This case highlights the importance of considering <jats:italic>enterovirus<\/jats:italic> encephalitis in immunocompromised patients presenting with both acute and chronic neurological signs, as well as developmental regression. The demonstrated treatment success and the associated low risk of toxicity warrant further investigation of this therapeutic regimen.<\/jats:p>","DOI":"10.3389\/fimmu.2022.930031","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T09:42:50Z","timestamp":1663062170000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Case report: Novel treatment regimen for enterovirus encephalitis in SCID"],"prefix":"10.3389","volume":"13","author":[{"given":"Kritika","family":"Chetty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iek","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Kaliakatsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Ignacio","family":"Gonzalez-Granado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Klapsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair","family":"Bamford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Breuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00671-09","article-title":"In vitro antiviral activity of V-073 against polioviruses","volume":"53","author":"Oberste","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1007\/BF00918150","article-title":"Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review","volume":"12","author":"Misbah","year":"1992","journal-title":"J Clin Immunol"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01375-15","article-title":"Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68","volume":"59","author":"Sun","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1016\/j.pediatrneurol.2016.06.014","article-title":"Treatment of chronic enterovirus encephalitis with fluoxetine in a patient with X-linked agammaglobulinemia","volume":"64","author":"Gofshteyn","year":"2016","journal-title":"Pediatr Neurolo"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01073-16","article-title":"In vitro assessment of combinations of enterovirus inhibitors against enterovirus 71","volume":"60","author":"Wang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2017.12.020","article-title":"Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus","volume":"151","author":"Bixler","year":"2018","journal-title":"Antiviral Res"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2022.04.035","article-title":"The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies","volume":"120","author":"Hung","year":"2022","journal-title":"Int J Infect Dis"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1080\/17512433.2022.2078701","article-title":"Favipiravir-based treatment for outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Lan","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B10","article-title":"Modeling favipiravir antiviral efficacy against emerging viruses: From animal studies to clinical trials","volume":"9","author":"Madelain","year":"2020","journal-title":"CPT: Pharmacometrics Syst Pharmacol"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)60232-X","article-title":"Favipiravir for children with Ebola","volume":"385","author":"Bouazza","year":"2015","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-015-0364-1","article-title":"Ebola Virus infection: Review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials","volume":"55","author":"Madelain","year":"2016","journal-title":"Clin Pharmacokinetics."},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000001090","article-title":"Enterovirus infections of the central nervous system in children: An update","volume":"35","author":"Rudolph","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"B14","article-title":"Enteroviruses in X-linked agammaglobulinemia: Update on epidemiology and therapy","volume":"4","author":"Bearden","year":"2016","journal-title":"J Allergy Clin Immunol: In Practice."},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00665","article-title":"Recurrent and sustained viral infections in primary immunodeficiencies","volume":"8","author":"Ruffner","year":"2017","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00013542-199701000-00004","article-title":"Enteroviral infections in the immunocompromised host","volume":"8","author":"Galama","year":"1997","journal-title":"Rev Res Med Microbiol"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bmt.1704359","article-title":"Enterovirus infections following T-cell depleted allogeneic transplants in adults","volume":"33","author":"Chakrabarti","year":"2004","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.930031\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T09:43:06Z","timestamp":1663062186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.930031\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":17,"alternative-id":["10.3389\/fimmu.2022.930031"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.930031","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"article-number":"930031"}}